Better understanding of how colon cancer develops and progresses

September 11, 2018, University of Luxembourg
Cancer cells. Credit: Dr. Cecil Fox, National Cancer Institute

Researchers from the University of Luxembourg have discovered a molecular mechanism that is responsible for the spread of cancer cells in the body and the development of metastases in patients with colon cancer. Their findings could help to develop treatments that inhibit tumor growth.

Colorectal cancer (CRC) is among the most prevalent cancer types worldwide, with an estimated 1.3 million new cases and almost 700,000 deaths per year. The vast majority of CRC-related deaths can be attributed to metastatic spreading of the disease. Therefore, it is of utmost clinical relevance to understand the biology that underlies cancer progression and metastasis initiation.

First step for the development of novel therapeutic strategies

The scientists from the Molecular Disease Mechanisms (MDM) group at the University of Luxembourg compared cancer cells derived from primary, i.e. initial, tumors to from the same patient. The researchers found that a group of small molecules, namely the miR-371~373 cluster, is responsible for the regulation of metastasis. In an interdisciplinary approach, combining experimental and computational analyses, the research team observed that the miR-371~373 cluster is deactivated in a specific population of very aggressive, fast-growing . After the scientists reactivated the cluster in a complex series of experiments, the growth of the metastatic cells slowed down significantly. "Cancer is a really complex disease. While our results are just one piece of the puzzle, they clearly contribute to a better understanding of tumor initiation and metastasis and might be an important first step for the development of novel therapeutic strategies," said Dr. Pit Ullmann, the lead author of the study that was published in the prestigious journal Cancer Research.

Together with national and international collaborators from the RWTH University Hospital Aachen, the Integrated BioBank of Luxembourg (IBBL), the Centre d"Investigation et d'Épidémiologie Clinique (CIEC), the Laboratoire National de Santé (LNS), and several hospitals around the country, especially the Centre Hospitalier Emile Mayrisch (CHEM), the researchers were able to validate their results in patient samples from a large Luxembourgish colon cancer collection. "This kind of study is only possible if several groups with different expertise collaborate. Our partners have been very important throughout the project in order to assess the clinical relevance of our findings in patients," commented Dr. Elisabeth Letellier, principal investigator of the study.

The large study was supported by the Luxembourg National Research Fund (FNR) and the Fondation Cancer. "Competitive research heavily relies on state-of-the-art techniques and the availability of high quality patient samples. The concerted effort of different groups, the interdisciplinary approach, and especially the financial support by the FNR, the Fondation Cancer, and other funding institutions were crucial for the successful completion of this project," said Prof. Serge Haan, the head of the MDM group.

Explore further: New biomarkers for colorectal cancer

More information: Pit Ullmann et al. The miR-371∼373 Cluster Represses Colon Cancer Initiation and Metastatic Colonization by Inhibiting the TGFBR2/ID1 Signaling Axis, Cancer Research (2018). DOI: 10.1158/0008-5472.CAN-17-3003

Related Stories

New biomarkers for colorectal cancer

January 11, 2018
For colorectal cancer (CRC), early detection and classification is important, as not all Stage II patients benefit from chemotherapy. Identifying patients at risk for recurrence during the early course of the disease might ...

New clues for the early detection of colorectal cancer

October 9, 2014
Researchers at the University of Luxembourg have identified potential new ways to test for the first signs of one of the most deadly types of cancer: colorectal cancer. They have found new "biomarkers": molecules whose increased ...

Scientists shed light on a tumor-suppressive protein in metastases

December 6, 2017
A new study conducted at the VIB-KU Leuven Center for Cancer Biology in Belgium has labeled the protein Caveolin-1 as a high-potential target in the fight against cancer. Many research projects have already implicated this ...

Targeting molecules called miR-200s and ADAR2 could prevent tumor metastasis in patients with colorectal cancer

April 24, 2018
Colorectal cancer is the third most common cancer worldwide and the third-leading cause of cancer-related deaths. The main cause of death in patients with colorectal cancer is liver metastasis, with nearly 70% of patients ...

Gene thought to suppress cancer may actually promote spread of colorectal cancer

January 4, 2016
A gene that is known to suppress the growth and spread of many types of cancer has the opposite effect in some forms of colorectal cancer, University of Missouri School of Medicine researchers have found. It is a finding ...

Researchers identify specific protein that helps breast cancer to spread

January 25, 2018
Researchers from the University's Institute of Translational Medicine have found an explanation for how breast cancer spreads to the lungs, which could potentially hold the key to preventing the progression of the disease.

Recommended for you

More clues revealed in link between normal breast changes and invasive breast cancer

October 15, 2018
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process—changes in mammary glands to accommodate breastfeeding—uses a molecular process believed ...

Cancer stem cells use 'normal' genes in abnormal ways

October 12, 2018
CDK1 is a "normal" protein—its presence drives cells through the cycle of replication. And MHC Class I molecules are "normal" as well—they present bits of proteins on the surfaces of cells for examination by the immune ...

Obesity linked to increased risk of early-onset colorectal cancer

October 12, 2018
Women who are overweight or obese have up to twice the risk of developing colorectal cancer before age 50 as women who have what is considered a normal body mass index (BMI), according to new research led by Washington University ...

Potential therapy for treatment-resistant hypothyroidism proves effective in lab study

October 12, 2018
A new "metal-coordinated" drug-delivery technology potentially could be used to supplement the standard therapy for hypothyroidism, which affects nearly 10 million Americans, and many more patients worldwide, according to ...

Researchers find a 'critical need' for whole genome sequencing of young cancer patients

October 12, 2018
St. Jude Children's Research Hospital has re-defined the gold standard for diagnostic testing of childhood cancer patients in the precision-medicine era and has implemented the testing for new cancer patients. The findings ...

Immune cells in triple-negative breast cancer offer potential therapeutic target

October 11, 2018
About 15 percent of breast cancers are classified as triple-negative, lacking receptors for estrogen, progesterone, and Her2. These cancers do not respond to targeted hormonal therapies, and they tend to be particularly aggressive, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.